Stock 603439 GUIZHOU SANLI PHARMACEUTICAL CO.,LTD
Add to a list
To use this feature you must be a member
Log inSign up

All News GuiZhou SanLi Pharmaceutical Co.,Ltd

Equities

603439

CNE1000040B4

End-of-day quote Shanghai S.E.
Other stock markets
 18:00:00 2024-06-05 EDT 		5-day change 1st Jan Change
14 CNY -2.57% Intraday chart for GuiZhou SanLi Pharmaceutical Co.,Ltd -6.10% -25.85%
04-26 Guizhou Sanli Pharmaceutical Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
04-26 Guizhou Sanli Pharmaceutical Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2023 CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Guizhou Sanli Pharmaceutical Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Guizhou Sanli Pharmaceutical Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Tranche Update on Guizhou Sanli Pharmaceutical Co.,Ltd's Equity Buyback Plan announced on November 4, 2023.
CI
Guizhou Sanli Pharmaceutical Co.,Ltd's Equity Buyback announced on November 4, 2023, has closed with 1,550,900 shares, representing 0.38% for CNY 29.99 million.
CI
Guizhou Sanli Pharmaceutical Co.,Ltd announces an Equity Buyback for CNY 40 million worth of its shares.
CI
Guizhou Sanli Pharmaceutical Co.,Ltd authorizes a Buyback Plan.
CI
Guizhou Sanli Pharmaceutical Co.,Ltd completed the acquisition of 50.26% stake in Guizhou Hanfang Pharmaceutical Co., Ltd. from Gui'an New District Shunqi Commercial Operation Management Center (Limited Partnership) and Sheng Yongjian.
CI
Shanghai Guosheng Haitong Private Enterprise High-Quality Development Private Investment Fund and Shanghai Guosheng Capital Management Co., Ltd. completed the acquisition of 5.0017% stake in Guizhou Sanli Pharmaceutical Co.,Ltd(SHSE:603439) from Wang Huiying.
CI
Guizhou Sanli Pharmaceutical Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023
CI
Guizhou Sanli Pharmaceutical Co.,Ltd agreed to acquire a stake in Guizhou Hanfang Pharmaceutical Co., Ltd. from Gui'an New District Shunqi Commercial Operation Management Center (Limited Partnership) and Sheng Yongjian
CI
Guizhou Sanli Pharma Plans Acquisition for CNY 499.6 Million
CI
Guizhou Sanli Pharmaceutical Co.,Ltd(XSSC:603439) added to S&P Global BMI Index
CI
Guizhou Sanli Pharmaceutical Co.,Ltd Reports Earnings Results for the Half Year Ended June 30, 2023
CI
Shanghai Guosheng Haitong Private Enterprise High-Quality Development Private Investment Fund and Shanghai Guosheng Capital Management Co., Ltd. entered into 5.0017% stake in Guizhou Sanli Pharmaceutical Co.,Ltd from Wang Huiying for CNY 322.875 million.
CI
GuiZhou SanLi Pharmaceutical Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
Certain A Shares of GuiZhou SanLi Pharmaceutical Co.,LTD. are subject to a Lock-Up Agreement Ending on 28-APR-2023.
CI
GuiZhou SanLi Pharmaceutical Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2022
CI
Guizhou Sanli Pharma Sees Up to 42.5% Jump in 2022 Profit
MT
Guizhou Sanli Pharma Elects Vice Chairman
MT
GuiZhou SanLi Pharmaceutical Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2022
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 603439 Stock
  4. News GuiZhou SanLi Pharmaceutical Co.,Ltd